An “Off-the-Shelf” CD2 Universal CAR-T Therapy for T Cell Malignancies

To broaden the use of CAR-T cells in pan T cell malignancies, researchers developed an allogeneic “universal” CD2-targeting CAR-T cell, in which the CD2 antigen is deleted to prevent fratricide, and the T cell receptor is removed to prevent graft-versus-host-disease.